Videos

Implications for using plinabulin as prophylaxis against chemotherapy-induced neutropenia alone or in combination with other therapies based on data revealed by the Protective-1 and Protective-2 trials.

An overview of the Protective-1 trial of single-agent plinabulin vs pegfilgrastim after docetaxel in patients with advanced breast cancer, advanced non–small cell lung cancer, and hormone-refractory prostate cancer.

Moshe Levy, MD discusses the ongoing phase 3b study of asciminib in patients with chronic myeloid leukemia in chronic phase.

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses unmet clinical needs in myelofibrosis.

Dr Andrew Gianoukakis reviews the study design and key efficacy data of the phase 3 DECISION and SELECT trials.

Andrew Gianoukakis, MD, reviews the NCCN guidelines for the treatment of patients with thyroid cancer.

Dr Andrew Gianoukakis, explores considerations surrounding systemic therapy in patients with RAI-refractory differentiated thyroid cancer.

Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.

Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.

The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.

Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.

Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.

Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.

In this second video of the series, Phillip J. Koo, MD, of the Banner MD Anderson Cancer Center explains the role of nuclear imaging (PET) and PSMA in the diagnosis and treatment of prostate cancer.

Ingrid Glimelius, MD, PhD, a senior lecturer and assistant professor in the Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala Universitet, discusses the lasting effects of lymphoma treatments.

Jorge E. Cortes, MD, discusses the current therapies available to treat patients with chronic myeloid leukemia and how to choose between them when there is similar efficacy.

Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.

An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.

Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.

A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.

Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.

Robert Coleman, MD, FACOG, FACS, discussed how immunotherapy in lung cancer has been widely accepted and adopted in the community oncology setting.

Tanios Bekaii-Saab, MD, FACP, concludes with a discussion of potential outcomes for a 65-year-old patient with stage 4 metastatic colorectal cancer.

Dr Bekaii-Saab reviews options for subsequent lines of therapy for metastatic colorectal cancer, including non-chemotherapy options.

An expert elaborates on the importance of the capecitabine + bevacizumab combination therapy for metastatic colorectal cancer, as well as what signs of progression or recurrence to look for in patients.

Dr Bekaii-Saab discusses therapy options for first-line treatment of metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, FACP, provides an overview of a case involving a 65-year-old man diagnosed with stage 4 metastatic colorectal cancer.

Lori Wirth, MD, discusses the relevance of patient-reported outcomes from the phase 1/2 LIBRETTO-001 study in of selpercatinib in patients with RET-altered medullary thyroid cancer or advanced thyroid cancer.

An expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.

Lyndsay Willmott, MD, explains the tolerability of PARP inhibitors for ovarian cancer and how to discuss dose reductions with patients.